Actively Recruiting
Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
Led by University of Edinburgh · Updated on 2026-01-14
60
Participants Needed
1
Research Sites
118 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Large vessel vasculitis (LVV) is a disease that causes damage to blood vessels. This damage to blood vessels can increase the risk of patients with LVV developing cardiovascular disease, including heart attacks and strokes. A chemical produced in the body called endothelin may contribute to this increase in cardiovascular disease risk by causing the vessels to stiffen and blood pressure to increase. It has previously been shown that by blocking the effects of endothelin, vessel stiffness and blood pressure improve. Bosentan is a tablet that blocks the effects of endothelin. Dapagliflozin is a sodium-glucose co-transporter 2 inhibitor that has been shown to improve blood vessel function and stiffness in patients with diabetes. The investigators plan to assess blood vessel function in those with LVV and participants without LVV. Participants with LVV will be given Bosentan and Dapagliflozin for 6 weeks, followed by Dapagliflozin for 4 weeks, to evaluate their impact on blood vessel function.
CONDITIONS
Official Title
Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of large vessel vasculitis that has been in remission for 6 months or more
You will not qualify if you...
- Age under 18 years
- Active large vessel vasculitis
- Organ transplant recipients
- Need for medications that cannot be taken with Bosentan or Dapagliflozin
- Congestive heart failure
- Not medically fit to attend study visits
- Unable or unwilling to provide informed consent
- History of multiple or severe allergic reactions to drugs or food
- Pregnant, breastfeeding, or planning pregnancy during the study
- Participation in another clinical trial within 28 days before or 90 days after this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Edinburgh
Edinburgh, United Kingdom, EH16 4TJ
Actively Recruiting
Research Team
A
Alex Armstrong
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here